Latest News
-
Monday - January 7, 2013
Following a detailed appraisal by the Cologne district authority:
Bayer gets the green light to build and operate the new world-scale TDI plant in Dormagen » more
-
Monday - January 7, 2013
Not intended for U.S. and UK media
Bayer Submits VEGF Trap-Eye (aflibercept) for Treatment of Macular Edema Following Central Retinal Vein Occlusion in Japan » more
-
Friday - January 4, 2013
Not intended for U.S. media
Bayer HealthCare completes acquisition of Teva’s U.S. animal health business
New product lines strengthen Bayer’s animal health business in the U.S. » more
-
Thursday - January 3, 2013
Not intended for U.S. and UK media
Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer » more
-
Friday - December 21, 2012
Not intended for U.S. and UK Media
Bayer Submits Regorafenib for the Treatment of Gastrointestinal Stromal Tumors in Japan » more
-
Wednesday - December 19, 2012
Bayer optimizes its use of liquidity
Group contributes EUR 1 billion to Bayer Pension Trust » more
-
Tuesday - December 18, 2012
New polycarbonate grades for furniture are clear winners
Bayer MaterialScience fulfills the wish of modern designers » more
-
Friday - December 14, 2012
Not intended for U.S. and UK Media
Bayer Submits New Drug Application to U.S. FDA for Radium-223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer with Bone Metastases
Radium-223 dichloride now submitted for Marketing Authorization in EU and US » more
-
Friday - December 14, 2012
Michael Koenig appointed to the Bayer Board of Management
Dr. Richard Pott to retire effective June 1, 2013 » more
-
Thursday - December 13, 2012
Bayer CropScience hosts inaugural Vegetable Future Forum in Monheim:
Partnerships key to success of global vegetable food value chain » more
-
Wednesday - December 12, 2012
Not intended for U.S. and UK Media
Bayer Submits Radium-223 Dichloride for EU Marketing Authorization for the Treatment of Castration-Resistant Prostate Cancer with Bone Metastases » more
-
Monday - December 10, 2012
Distinction for outstanding HR marketing activities:
Bayer JobApp wins HR Excellence Award » more
-
Thursday - December 6, 2012
Innovative and flexible solutions for reducing vehicle fleet CO2:
Bayer awarded International Fleet Green Award once again
Objective achieved ahead of deadline: 20 percent reduction in CO2 emissions of vehicle fleet since 2008 » more
-
Thursday - December 6, 2012
Not intended for U.S. and UK media
Bayer Submits VEGF Trap-Eye (aflibercept) for Treatment of Macular Edema Following Central Retinal Vein Occlusion in EU » more
-
Wednesday - December 5, 2012
Not intended for U.S. and UK Media
Bayer receives green light for new long-term contraceptive in the EU
Company plans to market the new low dose levonorgestrel-releasing intrauterine system under the brand name “Jaydess” / Product provides reliable contraception for up to three years » more
-
Friday - November 30, 2012
Science For A Better Life:
150 years of Bayer: Success through innovation and change
Dekkers: Bayer products have become indispensable to our lives / Numerous events planned in 2013 » more
-
Friday - November 30, 2012
Not intended for U.S. and UK Media: 54th American Society of Hematology (ASH) Annual Meeting and Exposition 2012:
New data on Bayer’s Xarelto® (Rivaroxaban) as a Single-Drug Solution for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Pooled data from EINSTEIN trials show oral rivaroxaban has an improved benefit-risk profile and lower rates of major bleeding compared with standard therapy / New data also show reduced hospital stay and improved patient-reported satisfaction with rivaroxaban for patients with acute symptomatic PE » more
-
Thursday - November 29, 2012
European Innovative Medicines Initiative (IMI):
Bayer supports pharmaceutical research in Europe
Bayer HealthCare and Leiden University coordinate consortium to optimize binding kinetics for drug candidates » more
-
Wednesday - November 28, 2012
New edition of research, the Bayer Scientific Magazine, published
Improving people’s lives through innovation
Systematic biotechnology: life science research for new therapies and a reliable food supply / Potatoes: head start for young tubers / Catalysis: turbocharged chemistry for innovative molecules » more
-
Wednesday - November 28, 2012
Not intended for U.S. and UK Media - Hemophilia solutions:
Bayer completes recruitment of first cohort for novel recombinant factor VIIa (rFVIIa) protein Phase II/III study
Investigational new treatment for Hemophilia A and Hemophilia B patients who have developed neutralizing antibodies » more
Copyright @ Bayer AG